Genetic variation of GPLD1 associates with serum GPI-PLD levels: a preliminary study.
暂无分享,去创建一个
[1] D. W. Moss,et al. Inositol-specific phospholipase D activity in health and disease. , 1994, Clinical science.
[2] A. Manatunga,et al. Longitudinal assessment of blood pressures in black and white children. , 1993, Hypertension.
[3] P. Bütikofer,et al. Subcellular distribution of glycosylphosphatidylinositol-specific phospholipase D in rat liver. , 1996, The Biochemical journal.
[4] M. Hoener,et al. Phosphatidylinositol-glycan-specific phospholipase D is an amphiphilic glycoprotein that in serum is associated with high-density lipoproteins. , 1992, European journal of biochemistry.
[5] N. Chalasani,et al. Glycosylphosphatidylinositol-specific phospholipase d in nonalcoholic Fatty liver disease: a preliminary study. , 2006, The Journal of clinical endocrinology and metabolism.
[6] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[7] M. G. Low,et al. Glycosylphosphatidylinositol-specific phospholipase D improves glucose tolerance. , 2010, Metabolism: clinical and experimental.
[8] Christian Gieger,et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma , 2011, Nature Genetics.
[9] Thomas Werner,et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites , 2005, Bioinform..
[10] S. Hurel,et al. Insulin reduces serum glycosylphosphatidylinositol phospholipase D levels in human type I diabetic patients and streptozotocin diabetic rats. , 2002, Molecular genetics and metabolism.
[11] J. Gruen,et al. Peaks of linkage are localized by a BAC/PAC contig of the 6p reading disability locus. , 2001, Genomics.
[12] L. Olson,et al. Mouse glycosylphosphatidylinositol-specific phospholipase D (Gpld1) characterization , 1998, Mammalian Genome.
[13] D. D’Alessio,et al. Plasma glycosylphosphatidylinositol-specific phospholipase D predicts the change in insulin sensitivity in response to a low-fat but not a low-carbohydrate diet in obese women. , 2008, Metabolism: clinical and experimental.
[14] J. Schofield,et al. Structure and expression of the human glycosylphosphatidylinositol phospholipase D1 (GPLD1) gene. , 2000, Biochimica et Biophysica Acta.
[15] G. Maguire,et al. Glycosyl Phosphatidyl Inositol Phospholipase D Activity in Human Serum , 1995, Annals of clinical biochemistry.
[16] N. Fineberg,et al. Insulin resistance is associated with increased serum levels of glycosylphosphatidylinositol-specific phospholipase D. , 2004, Metabolism: clinical and experimental.
[17] V. Nussenzweig,et al. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes , 1984, The Journal of experimental medicine.
[18] S. Tishkoff,et al. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. , 2008, Annual review of genomics and human genetics.
[19] M. Deeg,et al. Statin therapy reduces serum levels of glycosylphosphatidylinositol-specific phospholipase D. , 2007, Translational research : the journal of laboratory and clinical medicine.
[20] H. Brewer,et al. Characterization of high density lipoprotein-bound and soluble RT6 released following administration of anti-RT6.1 monoclonal antibody. , 1998, Journal of immunology.
[21] Scott M. Williams,et al. The Genetic Structure and History of Africans and African Americans , 2009, Science.
[22] M. Cheung,et al. GPI-specific phospholipase D associates with an apoA-I- and apoA-IV-containing complex. , 2001, Journal of lipid research.
[23] Luigi Ferrucci,et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. , 2008, American journal of human genetics.
[24] M. Deeg,et al. Glycosylphosphatidylinositol-specific phospholipase D influences triglyceride-rich lipoprotein metabolism. , 2006, American journal of physiology. Endocrinology and metabolism.
[25] Robert L Wilensky,et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.